Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
Karolina Aragon‐Gawinska, Charlotte Mouraux, Tamara Dangouloff, et al.
Genes (2023) Vol. 14, Iss. 7, pp. 1377-1377
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, et al.
JAMA Pediatrics (2024) Vol. 178, Iss. 6, pp. 540-540
Closed Access | Times Cited: 23
Spinal Muscular Atrophy Update in Best Practices
Mary Schroth, J. Deans, Kapil Arya, et al.
Neurology Clinical Practice (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 12
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
Janbernd Kirschner, G. Bernert, Nina Butoianu, et al.
European Journal of Paediatric Neurology (2024) Vol. 51, pp. 73-78
Open Access | Times Cited: 12
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Edmar Zanoteli, Alexandra Prufer de Queiroz Campos Araújo, Michele Michelin Becker, et al.
Arquivos de Neuro-Psiquiatria (2024) Vol. 82, Iss. 01, pp. 001-018
Open Access | Times Cited: 10
The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review
Claudia Dosi, Riccardo Masson
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice
Luisa Agnello, Caterina Maria Gambino, Anna Maria Ciaccio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4323-4323
Open Access | Times Cited: 9
Respiratory morbidity in patients with spinal muscular atrophy—a changing world in the light of disease-modifying therapies
Leen Lagae, Marijke Proesmans, M. van den Hauwe, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 8
Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy
Katy Cooper, Gamze Nalbant, Anthea Sutton, et al.
International Journal of Neonatal Screening (2024) Vol. 10, Iss. 3, pp. 49-49
Open Access | Times Cited: 7
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians
Sithara Ramdas, Maryam Oskoui, Laurent Servais
Drugs (2024) Vol. 84, Iss. 7, pp. 747-762
Closed Access | Times Cited: 5
Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy
Gianni Ghetti, Francesco Saverio Mennini, Andrea Marcellusi, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 9, pp. 687-701
Open Access | Times Cited: 5
Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium
Tamara Dangouloff, Praveen Thokala, Matt Stevenson, et al.
Neuromuscular Disorders (2023) Vol. 34, pp. 61-67
Open Access | Times Cited: 12
Universal Newborn Screening for Spinal Muscular Atrophy
Maryam Oskoui, Tamara Dangouloff, Laurent Servais
JAMA Pediatrics (2024) Vol. 178, Iss. 6, pp. 520-520
Closed Access | Times Cited: 4
Early spinal muscular atrophy treatment following newborn screening: A 20‐month review of the first Italian regional experience
Delia Gagliardi, Eleonora Canzio, Paola Orsini, et al.
Annals of Clinical and Translational Neurology (2024) Vol. 11, Iss. 5, pp. 1090-1096
Open Access | Times Cited: 4
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3
Federica Trucco, Deborah Ridout, Harriet Weststrate, et al.
Neurology Clinical Practice (2024) Vol. 14, Iss. 3
Closed Access | Times Cited: 4
Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy
Katy Cooper, Gamze Nalbant, Anthea Sutton, et al.
International Journal of Neonatal Screening (2024) Vol. 10, Iss. 3, pp. 56-56
Open Access | Times Cited: 4
Pushing the boundaries: future directions in the management of spinal muscular atrophy
Fiona Moultrie, Laura Chiverton, Isabel Hatami, et al.
Trends in Molecular Medicine (2025)
Open Access
Wearable sensors in paediatric neurology
Camila Gonzalez-Barral, Laurent Servais
Developmental Medicine & Child Neurology (2025)
Open Access
The Socio-Economic Burden of Spinal Muscular Atrophy: A Cost-of-Illness Study in Bulgaria
Elizabet Dzhambazova, Костадин Костадинов, Lilia Tsenkova-Toncheva, et al.
Healthcare (2025) Vol. 13, Iss. 4, pp. 401-401
Open Access
Spinal muscular atrophy in the UK: the human toll of slow decisions
Laurent Servais, Tamara Dangouloff, Francesco Muntoni, et al.
The Lancet (2025) Vol. 405, Iss. 10479, pp. 619-620
Closed Access
Prenatal treatment of spinal muscular atrophy
Laurent Servais
Molecular Therapy (2025)
Closed Access
Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan
Chen‐Hua Wang, Ting‐Rong Hsu, Mei‐Ying Liu, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 20, Iss. 1
Open Access
The Importance of Early Treatment of Inherited Neuromuscular Conditions
Laurane Mackels, Laurent Servais
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 253-274
Open Access | Times Cited: 3
Clinical Perspectives: Treating Spinal Muscular Atrophy
Molly McPheron, Marcia V. Felker
Molecular Therapy (2024) Vol. 32, Iss. 8, pp. 2489-2504
Closed Access | Times Cited: 3
Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing
Fumiyuki Hatanaka, Keiichiro Suzuki, Kensaku Shojima, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
Laurane Mackels, Virginie Mariot, L. Buscemi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8763-8763
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top